Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program


van den Eertwegh A. J. M. , Karakiewicz P., Bavbek S., Rha S. Y. , Bracarda S., Bahl A., ...More

UROLOGY, vol.81, no.1, pp.143-149, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 81 Issue: 1
  • Publication Date: 2013
  • Doi Number: 10.1016/j.urology.2012.09.019
  • Title of Journal : UROLOGY
  • Page Numbers: pp.143-149

Abstract

OBJECTIVE To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program.